Omada Health, Inc. (OMDA)
NASDAQ:OMDA
Top Page
Omada Health, Inc.
(NASDAQ:OMDA)
Select Model
Select Model
Rating:67Neutral
Price Target:
$13.50
▲(7.74% Upside)
Action:ReiteratedDate:03/07/26
The score is driven primarily by improving financial performance (rapid growth, margin expansion, positive 2025 operating/free cash flow, and a debt-free balance sheet) and a generally positive earnings-call outlook with continued EBITDA improvement guidance. Offsetting this are weak valuation support due to negative earnings and a mixed technical picture (negative MACD and price still below the 100-day average).
Positive Factors
Revenue growth & membership scale
Sustained, rapid top-line growth and material member adds show durable commercial traction with employers and plans. Growing membership and >25M covered lives expand TAM access and support recurring revenue, increasing the potential for long-term customer retention and scale economics.
Negative Factors
Profitability not yet consistent
Quarterly profitability is recent and uneven: a profitable quarter did not convert to full-year GAAP profit. That unevenness implies earnings vulnerability to seasonality, one‑time items, or cost swings, leaving sustainability of profits and ROE improvement unproven over multiple years.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue growth & membership scale
Sustained, rapid top-line growth and material member adds show durable commercial traction with employers and plans. Growing membership and >25M covered lives expand TAM access and support recurring revenue, increasing the potential for long-term customer retention and scale economics.
Read all positive factors
Omada Health, Inc. (OMDA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$738.34M
Dividend YieldN/A
Average Volume (3M)1.52M
Price to Earnings (P/E)―
Beta (1Y)2.24
Revenue Growth50.51%
EPS Growth50.92%
CountryUS
Employees849
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)0.08
Shares Outstanding58,925,438
10 Day Avg. Volume747,311
30 Day Avg. Volume1,515,662
Financial Highlights & Ratios
PEG Ratio0.97
Price to Book (P/B)4.01
Price to Sales (P/S)3.54
P/FCF Ratio54.46
Enterprise Value/Market Cap0.70
Enterprise Value/Revenue1.98
Enterprise Value/Gross Profit3.03
Enterprise Value/Ebitda-79.65
Forecast
1Y Price Target
$21.89Price Target Upside74.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-0.14
Revenue Forecast (FY)$318.89M
Omada Health, Inc. Business Overview & Revenue Model
Company Description
Omada Health is a U.S.-based virtual-care provider offering clinically validated programs for chronic conditions like cardiometabolic disease, musculoskeletal care, and behavioral health—delivered digitally between doctor visits....
How the Company Makes Money
null...
Omada Health, Inc. Earnings Call Summary
Earnings Call Date:Mar 05, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 14, 2026
Earnings Call Sentiment Positive
The call emphasized strong operational momentum in 2025 with substantial top-line growth (53%), scale in membership (886k, +55%), record margin expansion, first GAAP profitable quarter and positive full-year adjusted EBITDA—backed by product innovation (GLP-1 prescribing/Flex Care, cholesterol), AI deployment and peer-reviewed outcomes. Management provided prudent 2026 guidance (midpoint ~22% growth) that deliberately excludes early contributions from new products, which moderates near-term upside but reflects conservative planning. Near-term headwinds include seasonality-driven Q1 costs, a one-time Q4 revenue true-up, and the early-stage nature of new offerings; however, the balance of evidence points to durable commercial traction, improving unit economics and continued investment in scalable AI/product capabilities.Positive Updates
Strong Revenue Growth and Scale
Full-year 2025 revenue of $260 million, up 53% year-over-year; Q4 2025 revenue of $76 million, up 58% year-over-year. Members reached 886,000 at year-end, up 55% YoY with 314,000 net new members added in 2025 (55,000 net adds in Q4).
Negative Updates
Guidance Shows Deceleration vs 2025 Outperformance
2026 revenue guidance of $312–$322 million implies ~22% growth at the midpoint, a material slowdown from 53% growth in 2025. Management noted guidance excludes meaningful contributions from GLP-1 prescribing, GLP-1 Flex Care and cholesterol, and assumes no material improvement in enrollment conversion.
Read all updates
Q4-2025 Updates
Positive
Negative
Strong Revenue Growth and Scale
Full-year 2025 revenue of $260 million, up 53% year-over-year; Q4 2025 revenue of $76 million, up 58% year-over-year. Members reached 886,000 at year-end, up 55% YoY with 314,000 net new members added in 2025 (55,000 net adds in Q4).
Read all positive updates
Company Guidance
Omada guided 2026 revenue of $312–$322M (midpoint ≈ $317M, ~22% growth vs. 2025) and adjusted EBITDA of $7–$15M (midpoint ≈ $11M, ~+$5M vs. 2025), starting from a 2025 base of 886,000 members, >25M estimated covered lives, $260M revenue, $6M full‑year adjusted EBITDA (2% margin) and $222M cash; management expects Q1 roughly flat to Q4 (Q4 included a one‑time ~$2M true‑up), with Q1 seasonally heavier enrollment/device and care costs, did not assume meaningful contribution from GLP‑1 prescribing, GLP‑1 Flex Care or cholesterol nor material enrollment lift, and reiterated long‑term targets of >70% adjusted gross margin and 20%+ adjusted EBITDA margin while noting 2025 converted 40% of incremental revenue to adjusted EBITDA and ARPU is roughly just shy of $300 per ending member.Omada Health, Inc. Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
78
Positive
Cash Flow
70
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 260.21M | 169.80M | 122.78M | 89.19M |
| Gross Profit | 170.50M | 102.88M | 69.97M | 42.79M |
| EBITDA | -6.48M | -37.83M | -58.36M | -63.99M |
| Net Income | -12.78M | -47.14M | -67.51M | -72.52M |
Balance Sheet | ||||
| Total Assets | 305.41M | 150.89M | 175.08M | 221.80M |
| Cash, Cash Equivalents and Short-Term Investments | 222.04M | 76.39M | 115.64M | 168.12M |
| Total Debt | 0.00 | 30.19M | 30.58M | 30.81M |
| Total Liabilities | 75.73M | 86.26M | 76.16M | 66.19M |
| Stockholders Equity | 229.68M | 64.63M | 98.92M | 155.60M |
Cash Flow | ||||
| Free Cash Flow | 16.93M | -38.04M | -52.66M | -71.70M |
| Operating Cash Flow | 18.25M | -34.18M | -49.74M | -68.98M |
| Investing Cash Flow | -5.83M | -3.86M | -2.92M | -2.72M |
| Financing Cash Flow | 133.22M | -1.21M | 179.00K | 16.32M |
Omada Health, Inc. Risk Analysis
Omada Health, Inc. disclosed 73 risk factors in its most recent earnings report. Omada Health, Inc. reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Omada Health, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $738.34M | -72.16 | -7.10% | ― | 50.51% | 50.92% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $8.45M | -0.47 | -291.07% | ― | ― | 61.10% | |
44 Neutral | $1.99M | -0.18 | -145.52% | ― | ― | 97.70% | |
44 Neutral | $2.96M | -0.05 | -202.20% | ― | -49.63% | 82.22% | |
41 Neutral | $2.82M | >-0.01 | -112.81% | ― | -21.88% | 68.40% | |
40 Underperform | $7.17M | -1.29 | -220.42% | ― | -41.03% | 35.71% |
* Healthcare Sector Average
OMDA
Omada Health, Inc.
12.53
-10.07
-44.56%
ACXP
Acurx Pharmaceuticals
2.96
-3.62
-55.02%
HCTI
Healthcare Triangle
2.44
-3,433.76
-99.93%
BJDX
Bluejay Diagnostics
2.05
-7.87
-79.33%
TIVC
Tivic Health Systems
1.03
-3.79
-78.63%
HSCS
Heart Test Laboratories, Inc.
2.25
-0.80
-26.23%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.